Is acute myeloid leukemia a liquid tumor?
Open Access
- 30 December 2012
- journal article
- review article
- Published by Wiley in International Journal of Cancer
- Vol. 133 (3), 534-543
- https://doi.org/10.1002/ijc.28012
Abstract
Extramedullary manifestations of acute myeloid leukemia (AML) were described as early as the 19th century. However, the incidence, clinical significance and pathobiology of extramedullary AML remain ill defined. We reviewed case reports, retrospective case series, pilot studies and imaging studies of extramedullary leukemia (EML) to determine its frequency, characteristics, clinical presentation and significance. EML precedes or accompanies development of AML and occurs during or following treatment, even during remission. Although imaging studies are rarely conducted and the true incidence of EML has yet to be verified, authors have reported several estimates based on retrospective and autopsy studies. The incidence of EML in patients with AML of all ages is estimated to be about 9% and EML in children with AML was detected in 40% of patients at diagnosis. The combination of positron emission tomography and computed tomography were the most sensitive and reliable techniques of detecting and monitoring EML. Based on our literature review, the frequency of EML is likely underreported. The well‐documented nature of EML in patients with AML suggests that AML can manifest as a solid tumor. The extent to which EML accompanies AML and whether EML is derived from bone marrow are unknown. Furthermore, questions remain regarding the role of the microenvironment, which may or may not facilitate the survival and proliferation of EML, and the implications of these interactions with regard to minimal residual disease, tumor cell quiescence and relapse. Therefore, prospective studies of detection and characterization of EML in patients with AML are warranted.This publication has 101 references indexed in Scilit:
- How I treat extramedullary acute myeloid leukemiaBlood, 2011
- Myeloid sarcoma: current approach and therapeutic optionsTherapeutic Advances in Hematology, 2011
- Leptomeningeal myelomatosis in previously treated high-risk kappa light chain multiple myeloma: case report and literature reviewBlood and Lymphatic Cancer: Targets and Therapy, 2011
- Granulocytic sarcoma of the small bowel, greater omentum and peritoneum associated with a CBFbeta/MYH11 fusion and inv(16) (p13q22): a case reportInternational Archives of Medicine, 2011
- Recurrent Neurotropic Chloroma: Report of a Case and Review of the LiteratureAdvances in Hematology, 2010
- The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse modelBlood, 2010
- Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafishBlood, 2010
- Role of leukemia cell invadosome in extramedullary infiltrationBlood, 2009
- Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemiaCancer, 2008
- Granulocytic sarcoma: 32 cases and review of the literatureLeukemia & Lymphoma, 2006